Rubius Therapeutics Inc (NASDAQ:RUBY) Stake Lifted by Fmr LLC

FMR LLC lifted its stake in Rubius Therapeutics Inc (NASDAQ:RUBY) by 8.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,019,730 shares of the company’s stock after purchasing an additional 573,662 shares during the quarter. FMR LLC owned about 8.78% of Rubius Therapeutics worth $127,057,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in RUBY. Baillie Gifford & Co. lifted its stake in shares of Rubius Therapeutics by 1.9% during the 1st quarter. Baillie Gifford & Co. now owns 4,132,851 shares of the company’s stock worth $74,804,000 after acquiring an additional 76,655 shares during the last quarter. BlackRock Inc. raised its position in shares of Rubius Therapeutics by 52.9% in the 4th quarter. BlackRock Inc. now owns 2,430,505 shares of the company’s stock worth $39,083,000 after acquiring an additional 840,707 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Rubius Therapeutics in the 1st quarter worth $14,995,000. JPMorgan Chase & Co. raised its position in shares of Rubius Therapeutics by 82.5% in the 1st quarter. JPMorgan Chase & Co. now owns 604,669 shares of the company’s stock worth $10,944,000 after acquiring an additional 273,272 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in Rubius Therapeutics by 68.1% during the 1st quarter. ARK Investment Management LLC now owns 529,615 shares of the company’s stock worth $9,586,000 after buying an additional 214,463 shares during the last quarter. Hedge funds and other institutional investors own 93.75% of the company’s stock.

In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 47,757 shares of the firm’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total value of $669,553.14. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Langer sold 7,500 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $14.94, for a total value of $112,050.00. The disclosure for this sale can be found here. Company insiders own 58.40% of the company’s stock.

Several research analysts recently weighed in on RUBY shares. Zacks Investment Research upgraded Catasys from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Thursday. Guggenheim reiterated a “hold” rating on shares of Burlington Stores in a research note on Thursday, May 30th. Finally, HC Wainwright reissued a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Rubius Therapeutics presently has an average rating of “Buy” and a consensus target price of $31.00.

Shares of RUBY stock traded up $0.01 during trading hours on Thursday, reaching $14.93. The company had a trading volume of 277,232 shares, compared to its average volume of 283,415. The company has a debt-to-equity ratio of 0.13, a current ratio of 18.64 and a quick ratio of 18.64. The stock has a fifty day simple moving average of $14.69. The firm has a market cap of $1.18 billion and a P/E ratio of -6.58. Rubius Therapeutics Inc has a 12-month low of $12.70 and a 12-month high of $27.73.

Rubius Therapeutics (NASDAQ:RUBY) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04). As a group, analysts anticipate that Rubius Therapeutics Inc will post -1.84 earnings per share for the current fiscal year.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Recommended Story: What is a Fiduciary?

Institutional Ownership by Quarter for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.